Free Trial
→ Recession Risk: 90% — Are Your Savings Ready? (From Lear Capital) (Ad)tc pixel
NASDAQ:ICU

SeaStar Medical Q4 2023 Earnings Report

SeaStar Medical logo
$1.24 +0.08 (+6.90%)
Closing price 04:00 PM Eastern
Extended Trading
$0.67 -0.57 (-46.05%)
As of 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

SeaStar Medical EPS Results

Actual EPS
-$4.75
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

SeaStar Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SeaStar Medical Announcement Details

Quarter
Q4 2023
Date
4/16/2024
Time
N/A
Conference Call Date
Wednesday, April 17, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

SeaStar Medical's Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled at 3:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

SeaStar Medical's Q4 2023 Earnings ReleaseEarnings Release
(8-K)

SeaStar Medical Earnings Headlines

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/24/3155862/0/en/seastar-medical-reports-dsmb-recommendation-to-continue-the-neutralize-aki-pivotal-trial-in-adult-acute-kidney-injury.html
SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children
September 23 at 8:23 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/23/3154668/0/en/seastar-medical-to-present-early-save-registry-data-of-quelimmune-in-pediatric-acute-kidney-injury-at-the-5th-international-symposium-on-acute-kidney-injury-in-children.html
Arizona-made nanochips the new millionaire maker?
George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.tc pixel
September 24 at 2:00 AM  |  Banyan Hill Publishing (Ad)
SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference
September 4, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/04/3145037/0/en/seastar-medical-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference.html
SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated ...
September 2, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/seastar-medical-announces-newly-published-122200533.html
SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival
September 2, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/02/3142664/0/en/seastar-medical-announces-newly-published-quelimmune-health-economic-study-projecting-significantly-reduced-health-care-costs-in-the-treatment-of-pediatric-aki-due-to-estimated-sho.html
See More SeaStar Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SeaStar Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SeaStar Medical and other key companies, straight to your email.

About SeaStar Medical

SeaStar Medical (NASDAQ:ICU), Inc. (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR. TriGUARD 3 features an advanced frame and filter design that conforms to varying patient anatomies, enabling physicians to position the device safely and effectively without obstructing critical arterial access routes. SeaStar Medical continues to invest in clinical trials and registry studies to demonstrate the safety and performance of its technology and to support regulatory clearances in North America, Europe and other key markets.

Headquartered in Kansas City, Missouri, SeaStar Medical serves a global customer base through direct sales and distribution partnerships in Europe and parts of Asia Pacific, in addition to its U.S. operations. The company collaborates with interventional cardiologists, cardiac surgeons and research institutions to refine device design and expand indications. Its leadership team brings extensive experience from leading cardiovascular and medical device firms, guiding SeaStar Medical through product development, regulatory interactions and market introduction efforts to address the growing demand for neuroprotection in structural heart care.

View SeaStar Medical Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles